<DOC>
	<DOCNO>NCT02531360</DOCNO>
	<brief_summary>The overall goal image trial characterize [ 18F ] MNI-815 , PET radioligand image Tau .</brief_summary>
	<brief_title>Evaluation 18FMNI-815 Potential PET Radioligand Imaging Tau Protein Brain Patients With Tauopathies</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<mesh_term>Tauopathies</mesh_term>
	<criteria>For subject : Written inform consent must obtain assessment perform . Female subject must either surgically sterile ( mean hysterectomy , bilateral oophorectomy , tubal ligation ) postmenopausal least 1 year , childbearing potential , must commit use barrier contraception method duration study . Male subject partner childbearing potential must commit use two method contraception , one barrier method male subject study duration Willing able cooperate study procedures Healthy Control subject : Males female age 50 70 year . Healthy clinically relevant find physical examination screen upon report [ 18F ] MNI815 image visit . No cognitive impairment neuropsychological battery judge investigator Have CDR score=0 Has FBB PET image demonstrate evidence significant amyloid binding base qualitative ( visual read ) quantitative analysis . Modified Hachinski Ischemia Scale score ≤ 4 . Prodromal Moderate Alzheimer 's Disease subject : Males female age 50 90 year . Have prodromal moderate Alzheimer 's disease , base NINCDS/ADRDA DSMIV criterion . Have CDR score 0.5 prodromal AD subject CDR &gt; 1.0 moderate AD subject screening . Has FBB PET image demonstrate amyloid binding base qualitative ( visual read ) quantitative analysis . Modified Hachinski Ischemia Scale score ≤ 4 . A brain MRI support diagnosis AD , evidence focal disease account dementia MRI exclusion criterion . Medications take symptomatic treatment AD must maintain stable dosage regimen least 1 month [ 18F ] MNI815 image visit . The subject appropriate caregiver capable accompany subject visit . Signed date write informed consent obtain subject , applicable , subject 's legally authorize representative caregiver . Frontotemporal Dementia subject : Has clinical diagnosis FTD base consensus clinical diagnosis frontotemporal dementia criterion ( Neary , et al 1998 ) Has FBB PET image demonstrate evidence significant amyloid binding base qualitative ( visual read ) quantitative analysis . A brain MRI support diagnosis FTD , evidence focal disease account dementia MRI exclusion criterion . Medications take symptomatic treatment cognitive dysfunction must maintain stable dosage regimen least 1 month screen visit . The subject appropriate caregiver capable accompany subject visit center . Signed date write informed consent obtain subject , applicable , subject 's legally authorize representative caregiver . Modified Hachinski Ischemia Scale score ≤ 4 . Progressive Supranuclear Palsy subject : Has clinical diagnosis PSP base NINDS Society PSP criterion ( Litvan , et al 1996 ) Has FBB PET image demonstrate evidence significant amyloid binding base qualitative ( visual read ) quantitative analysis . A brain MRI support diagnosis PSP , evidence focal disease account dementia MRI exclusion criterion . Medications take treatment PSP symptom must maintain stable dosage regimen least 1 month screen visit . The subject appropriate caregiver capable accompany subject visit center . Signed date write informed consent obtain subject , applicable subject 's legally authorize representative caregiver . Modified Hachinski Ischemia Scale score ≤ 4 . Corticobasal Syndrome Subjects : Has clinical diagnosis CBS base consensus criterion possible probable corticobasal degeneration ( Armstrong et al , 2013 ) Has FBB PET image demonstrate evidence significant amyloid binding base qualitative ( visual read ) quantitative analysis . A brain MRI support diagnosis CBS , evidence focal disease account dementia MRI exclusion criterion . Medications take treatment CBS symptom must maintain stable dosage regimen least 1 month screen visit . The subject appropriate caregiver capable accompany subject visit center . Signed date write informed consent obtain subject , applicable , subject 's legally authorize representative caregiver . Modified Hachinski Ischemia Scale score ≤ 4 . For subject Current prior history alcohol drug abuse . Laboratory test clinically significant abnormality and/or clinically significant unstable medical illness . Prior participation research protocols clinical care last year radiation exposure &gt; 15 mSv would exceed annual limit . Pregnancy breastfeed . Evidence clinically significant gastrointestinal , cardiovascular , hepatic , renal , hematological , neoplastic , endocrine , alternative neurological , immunodeficiency , pulmonary , disorder disease . Unsuitable vein repeat venipuncture . MRI exclusion criterion include : Pathology may responsible neurologic status patient infectious disease , spaceoccupying lesion , normal pressure hydrocephalus abnormality associate CNS disease , Implants implant cardiac pacemaker defibrillator , insulin pump , cochlear implant , metallic ocular foreign body , implanted neural stimulators , CNS aneurysm clip medical implant certify MRI , history claustrophobia MRI . Exclusion criterion subject AD subject : Has receive treatment target amyloidbeta tau within last 24 month . Has FBB PET image demonstrate evidence significant amyloid bind irrespective previous measurement beta amyloid may available review . Exclusion criterion subject PSP CBS subject : Has FBB PET image evidence significant amyloid bind irrespective previous measurement beta amyloid may available review . Has receive treatment target tau within last 24 month . Have neurological condition CBS PSP could account cognitive motor deficit include : Specifically : A diagnosis idiopathic Parkinson 's disease Lewy body dementia and/or prominent sustain response levodopa therapy ; History repeat stroke stepwise progression parkinsonian feature history major stroke FTD subject : Has FBB PET image evidence significant amyloid bind irrespective previous measurement beta amyloid may available review . Has receive treatment target tau within last 24 month . Healthy subject : •Has FBB PET image evidence significant amyloid bind irrespective previous measurement beta amyloid may available review .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>